Orexo Appoints Robert A. DeLuca as President of Orexo US Inc.

Orexo Appoints Robert A. DeLuca as President of Orexo US Inc.

Uppsala, Sweden - July 1, 2013 – Orexo AB announces today that it has appointed
Robert A. DeLuca, as President of Orexo US Inc., a fully owned US subsidiary of
Orexo AB. Orexo US Inc will focus on commercialization of Zubsolv™
(buprenorphine and naloxone, sublingual tablets) in collaboration with the
appointed partner Publicis Touchpoint Solutions. With the establishment of a
commercial leadership team in the US, Orexo AB in Sweden will focus its
resources on the development of new products including product extensions of
Zubsolv, manufacturing and quality assurance and provide overall corporate
governance. Mr. DeLuca will become a member of the Executive Management team of
Orexo AB.

Robert A. DeLuca brings an extensive and relevant experience from establishing
commercial operations in the US, which will be important for the launch of
Zubsolv in September 2013. DeLuca has extensive experience within managed care,
marketing and sales from various leadership positions at Sanofi, Schering
-Plough, Berlex, Pharmacia and most recently as Chief Commercial Officer at
Archimedes Pharma.

DeLuca is a New Jersey licensed pharmacist and graduated from St. John's
University in New York City. DeLuca is on the St. John's College of Pharmacy
Advisory Board, serves on the Board of Trustees of the Academy of Managed Care
Pharmacy Foundation, and is a member of the Academy of Managed Care Pharmacy
(AMCP) and the American and New Jersey Pharmacists Association.

"Orexo provides an exciting opportunity and I have great expectations for the
launch of Zubsolv in the United States. I am impressed with the product profile,
especially the data from the acceptance trial, in which 89 percent of trial
participants favored Zubsolv over the conventional buprenorphine treatment
modalities for opioid addiction. We feel this product will address one of the
major health issues in the US and I am looking forward to establishing a strong
organization to execute the launch of Zubsolv in a market with significant
growth potential," said Robert A. DeLuca, President of Orexo US Inc.

"Establishing a commercial presence in the US is a key milestone towards the
launch of Zubsolv and I am particularly pleased that we have succeeded in
recruiting Mr. DeLuca to establish and lead our US subsidiary and the launch of
Zubsolv. He brings extensive experience in establishing commercial operations in
the US and his background in managed care will be a major asset to ensure a
successful launch of Zubsolv," said Nikolaj Sørensen, President and CEO of Orexo

With the appointment of Robert A. DeLuca, Orexo AB will activate the subsidiary
Orexo US Inc. registered in the state of Delaware.

For further information, please contact:
Nikolaj Sørensen, President and CEO, Orexo AB
Tel: +46 70-350 78 88, E-mail: [email protected]

Robert A. DeLuca, President, Orexo US Inc
Tel: + 1 201 953 1349, E-mail: [email protected]

About Orexo
Orexo is an emerging specialty pharma company developing improved treatments
using proprietary drug delivery technology. Orexo's expertise is within the area
of reformulation technologies and especially sublingual formulations. The
company has a portfolio of revenue-generating US and EU approved products
currently marketed under license and a pipeline of several reformulations of
approved compounds for areas of unmet medical need. Orexo also has collaboration
projects with several international pharma companies. Orexo, with its
headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are
Novo A/S and HealthCap.

About Zubsolv™
Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using
Orexo's extensive knowledge in sublingual technologies. Zubsolv is intended for
maintenance treatment of people suffering from opioid dependence. Through
application of its proprietary technologies Orexo has increased the
bioavailability of the active ingredient, accelerated dissolve time, reduced
tablet size and improved taste. In a comparative acceptability study 9 out of 10
participants choose Zubsolv over the market leader Suboxone Film for a daily
treatment. Zubsolv has the potential to be the leading product on a growing USD
1.5 billion market, with more than five million patients suffering from opioid
dependence and where a majority of patients are not adequately treated today.
Market potential for Zubsolv is at peak estimated at above USD 500 million in
sales annually.

For more information about Orexo please visit www.orexo.com.

Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 09:30am CET on July 1, 2013